Lower-extremity arterial endovascular stenting

D. F. Cikrit, Michael Dalsing

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Intraluminal arterial stenting for the management of arterial occlusive disease of the lower extremities has evolved over the years. Most stents are used to correct inadequacies of PTA or to correct a PTA complication. These include (1) restenosis within 90 days of PTA, (2) chronic iliac occlusion, (3) acute occlusions during PTA, (4) a significant residual gradient following PTA, (5) dissections longer than the angioplasty site, and (6) a 30% or greater residual stenosis after PTA. Both the Palmaz stent and the Wallstent have performed well in the iliac artery system. Their use in the femoropopliteal system has not been as successful and should be reserved for selected cases. Long-term anticoagulation is generally required for femoropopliteal stent patency. Placement in the lower superficial femoral or popliteal artery is best avoided. Reangioplasty or additional stenting may be used to prolong patency, although with the risk of a second intervention, Progression of arteriosclerosis is a factor to consider when choosing an endoluminal treatment versus standard bypass.

Original languageEnglish
Pages (from-to)617-629
Number of pages13
JournalSurgical Clinics of North America
Volume78
Issue number4
StatePublished - 1998

Fingerprint

Stents
Lower Extremity
Popliteal Artery
Arterial Occlusive Diseases
Arteriosclerosis
Iliac Artery
Femoral Artery
Angioplasty
Dissection
Pathologic Constriction
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Lower-extremity arterial endovascular stenting. / Cikrit, D. F.; Dalsing, Michael.

In: Surgical Clinics of North America, Vol. 78, No. 4, 1998, p. 617-629.

Research output: Contribution to journalArticle

@article{6fff2dceaa9b4735a79535c42e67b122,
title = "Lower-extremity arterial endovascular stenting",
abstract = "Intraluminal arterial stenting for the management of arterial occlusive disease of the lower extremities has evolved over the years. Most stents are used to correct inadequacies of PTA or to correct a PTA complication. These include (1) restenosis within 90 days of PTA, (2) chronic iliac occlusion, (3) acute occlusions during PTA, (4) a significant residual gradient following PTA, (5) dissections longer than the angioplasty site, and (6) a 30{\%} or greater residual stenosis after PTA. Both the Palmaz stent and the Wallstent have performed well in the iliac artery system. Their use in the femoropopliteal system has not been as successful and should be reserved for selected cases. Long-term anticoagulation is generally required for femoropopliteal stent patency. Placement in the lower superficial femoral or popliteal artery is best avoided. Reangioplasty or additional stenting may be used to prolong patency, although with the risk of a second intervention, Progression of arteriosclerosis is a factor to consider when choosing an endoluminal treatment versus standard bypass.",
author = "Cikrit, {D. F.} and Michael Dalsing",
year = "1998",
language = "English",
volume = "78",
pages = "617--629",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Lower-extremity arterial endovascular stenting

AU - Cikrit, D. F.

AU - Dalsing, Michael

PY - 1998

Y1 - 1998

N2 - Intraluminal arterial stenting for the management of arterial occlusive disease of the lower extremities has evolved over the years. Most stents are used to correct inadequacies of PTA or to correct a PTA complication. These include (1) restenosis within 90 days of PTA, (2) chronic iliac occlusion, (3) acute occlusions during PTA, (4) a significant residual gradient following PTA, (5) dissections longer than the angioplasty site, and (6) a 30% or greater residual stenosis after PTA. Both the Palmaz stent and the Wallstent have performed well in the iliac artery system. Their use in the femoropopliteal system has not been as successful and should be reserved for selected cases. Long-term anticoagulation is generally required for femoropopliteal stent patency. Placement in the lower superficial femoral or popliteal artery is best avoided. Reangioplasty or additional stenting may be used to prolong patency, although with the risk of a second intervention, Progression of arteriosclerosis is a factor to consider when choosing an endoluminal treatment versus standard bypass.

AB - Intraluminal arterial stenting for the management of arterial occlusive disease of the lower extremities has evolved over the years. Most stents are used to correct inadequacies of PTA or to correct a PTA complication. These include (1) restenosis within 90 days of PTA, (2) chronic iliac occlusion, (3) acute occlusions during PTA, (4) a significant residual gradient following PTA, (5) dissections longer than the angioplasty site, and (6) a 30% or greater residual stenosis after PTA. Both the Palmaz stent and the Wallstent have performed well in the iliac artery system. Their use in the femoropopliteal system has not been as successful and should be reserved for selected cases. Long-term anticoagulation is generally required for femoropopliteal stent patency. Placement in the lower superficial femoral or popliteal artery is best avoided. Reangioplasty or additional stenting may be used to prolong patency, although with the risk of a second intervention, Progression of arteriosclerosis is a factor to consider when choosing an endoluminal treatment versus standard bypass.

UR - http://www.scopus.com/inward/record.url?scp=0031825163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031825163&partnerID=8YFLogxK

M3 - Article

C2 - 9728204

AN - SCOPUS:0031825163

VL - 78

SP - 617

EP - 629

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 4

ER -